glp 1 drugs for non diabetics GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Non-Diabetic Patients on GLP-1 Medications

Koike, M

Additional doses may be taken before other meals as well.

When medically appropriate, we prescribe GLP-1s for conditions like cardiac and vascular disease, sleep apnea, kidney disease, type 2 diabetes and stroke risk

This mechanism amplifies existing HGF signaling rather than bypassing it: HGF Potentiation: Dihexa binds to HGF and stabilizes its active conformation, increasing c-Met receptor activation at physiologically relevant HGF concentrations Synaptogenesis: In vitro studies reported that Dihexa promoted new synapse formation at picomolar concentrations orders of magnitude more potent than BDNF in this specific assay Dendritic Spine Formation: Preclinical data suggested increases in dendritic spine density in hippocampal neurons, a structural correlate of learning and memory Oral Bioavailability: Unlike most peptides, Dihexa's small size and peptidomimetic structure may allow oral absorption and blood-brain barrier penetration Cerebrolysin: Multi-Neurotrophic Factor Cocktail Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids obtained by enzymatic breakdown of porcine brain tissue

Journal of Functional Foods 15, 2334 (2015)